
  
    
      
        Introduction_NNP
        Recombinant_NNP human_JJ interleukin-_NN 11_CD (_( rhIL-_NN 11_CD )_) is_VBZ a_DT
        pleiotropic_JJ cytokine_NN that_WDT regulates_VBZ the_DT growth_NN and_CC
        development_NN of_IN hematopoietic_JJ stem_NN cells_NNS and_CC decreases_NNS the_DT
        proinflammatory_NN mediators_NNS of_IN cytokine_NN and_CC nitric_JJ oxide_NN
        production_NN [_NN 1_CD ]_NN ._. Treatment_NNP with_IN rhIL-_NN 11_CD decreases_NNS the_DT
        production_NN of_IN proinflammatory_NN cytokines_NNS ,_, including_VBG tumor_NN
        necrosis_NNS factor_NN (_( TNF_NNP )_) -_: α_NN and_CC interleukin_NN (_( IL_NNP )_) -_: 1_CD β_NN ,_, and_CC
        inhibits_NNS NF-κB_NNP binding_JJ activity_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. In_IN animal_NN
        models_NNS both_DT of_IN collagen-induced_JJ and_CC adjuvant-induced_JJ
        arthritis_NN ,_, rhIL-_NN 11_CD reduced_VBD both_DT the_DT level_NN of_IN synovitis_NNS and_CC
        the_DT histologic_JJ lesion_NN score_NN in_IN the_DT joints_NNS [_NN 5_CD ]_NN ._.
        Rheumatoid_NNP arthritis_NN (_( RA_NNP )_) is_VBZ a_DT chronic_JJ inflammatory_JJ
        disease_NN of_IN unknown_JJ etiology_NN ._. Its_PRP$ worldwide_NN prevalence_NN is_VBZ
        approximately_RB 1_CD %_NN [_NN 6_CD ]_NN ._. There_EX appears_VBZ to_TO be_VB no_DT single_JJ
        therapeutic_JJ regimen_NN or_CC combination_NN of_IN therapies_NNS that_WDT has_VBZ
        consistently_RB been_VBN associated_VBN with_IN sustained_VBN improvement_NN
        (_( i_NNP ._. e_SYM ._. remission_NN )_) [_NN 7_CD ]_NN ._. A_DT number_NN of_IN disease-modifying_JJ drugs_NNS
        (_( e_SYM ._. g_SYM ._. methotrexate_NN )_) are_VBP available_JJ to_TO treat_VB RA_NNP but_CC are_VBP
        limited_VBN by_IN significant_JJ toxicity_NN requiring_VBG adjunct_NN therapy_NN ,_,
        or_CC are_VBP of_IN variable_JJ efficacy_NN ._. There_EX are_VBP currently_RB a_DT number_NN
        of_IN anticytokine_NN and_CC other_JJ immune-modulating_JJ therapies_NNS in_IN
        clinical_JJ trials_NNS [_NN 8_CD ]_NN ._. The_DT proinflammatory_NN cytokine_NN TNF_NNP has_VBZ
        been_VBN shown_VBN to_TO play_VB a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN RA_NNP [_NN 9_CD ,_,
        10_CD ]_NN ._. Etanercept_NNP (_( sTNFR_NN :_: Fc_NNP )_) and_CC infliximab_NN (_( chimeric_JJ
        anti-_NN TNF_NNP monoclonal_NN antibody_NN )_) have_VBP been_VBN shown_VBN to_TO be_VB
        efficacious_JJ in_IN the_DT treatment_NN of_IN patients_NNS with_IN RA_NNP for_IN whom_WP
        treatment_NN with_IN at_IN least_JJS one_CD disease-modifying_JJ antirheumatic_JJ
        drug_NN had_VBD previously_RB failed_VBN [_NN 11_CD ,_, 12_CD ]_NN ;_: both_DT of_IN these_DT
        biologicals_NNS have_VBP been_VBN approved_VBN by_IN regulatory_JJ agencies_NNS for_IN
        the_DT treatment_NN of_IN patients_NNS with_IN RA_NNP ._.
        rhIL-_NN 11_CD has_VBZ previously_RB been_VBN assessed_VBN in_IN a_DT Phase-_NNP I_PRP /_NN II_NNP ,_,
        masked_VBN ,_, placebo-controlled_JJ trial_NN in_IN patients_NNS with_IN active_JJ
        Crohn_NNP 's_POS disease_NN ._. The_DT data_NNS suggested_VBD clinical_JJ benefit_NN as_IN
        assessed_VBN from_IN the_DT mean_JJ change_NN from_IN baseline_NN in_IN the_DT Crohn_NNP 's_POS
        Disease_NNP Severity_NNP Index_NNP after_IN 21_CD days_NNS at_IN doses_NNS of_IN 16_CD and_CC 40_CD
        μg_NN /_NN kg_NN per_IN week_NN (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT researchers_NNS
        concluded_VBD that_DT rhIL-_NN 11_CD was_VBD safe_JJ at_IN the_DT doses_NNS and_CC schedules_NNS
        used_VBN and_CC had_VBN a_DT therapeutic_JJ effect_NN [_NN 13_CD ,_, 14_CD ]_NN ._. The_DT findings_NNS
        supported_VBD the_DT initiation_NN of_IN a_DT phase-_NN I_PRP /_NN II_NNP clinical_JJ trial_NN in_IN
        patients_NNS with_IN RA_NNP ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Patients_NNS
          Men_NN and_CC women_NNS at_IN least_JJS 18_CD years_NNS of_IN age_NN were_VBD eligible_JJ
          to_TO participate_VB if_IN they_PRP had_VBD met_VBN the_DT American_NNP College_NNP of_IN
          Rheumatology_NNP (_( ACR_NNP )_) criteria_NNS for_IN RA_NNP for_IN at_IN least_JJS one_CD year_NN
          and_CC were_VBD in_IN functional_JJ Class_NNP I_PRP ,_, II_NNP ,_, or_CC III_NNP [_NN 15_CD ]_NN ._. All_DT
          patients_NNS had_VBD to_TO have_VB had_VBN at_IN least_JJS one_CD failed_VBD trial_NN of_IN a_DT
          disease-modifying_JJ antirheumatic_JJ drug_NN (_( DMARD_NNP )_) and_CC had_VBD to_TO
          have_VB at_IN least_JJS 10_CD painful_JJ and_CC 10_CD swollen_JJ joints_NNS at_IN entry_NN ._.
          No_DT DMARD_NNP therapy_NN was_VBD allowed_VBN within_IN 4_CD weeks_NNS of_IN
          randomization_NN ._. Patients_NNS receiving_VBG nonsteroidal_NN
          anti-inflammatory_JJ drugs_NNS ,_, corticosteroids_NNS (_( ≤_NN 10_CD mg_NN per_IN
          day_NN )_) ,_, or_CC both_DT were_VBD allowed_VBN in_IN the_DT trial_NN if_IN they_PRP had_VBD been_VBN
          on_IN stable_JJ doses_NNS for_IN at_IN least_JJS four_CD weeks_NNS before_IN
          randomization_NN ._. Required_NNP baseline_NN laboratory_NN values_NNS
          included_VBD serum_NN creatinine_NN and_CC blood_NN urea_NN nitrogen_NN ≤_NN 1_CD ._. 5_CD ×_NN
          the_DT upper_JJ limit_NN of_IN normal_JJ and_CC alanine_NN aminotranferase_NN and_CC
          aspartate_NN aminotransferase_NN ≤_NN 2_CD ._. 0_CD ×_NN the_DT upper_JJ limit_NN of_IN
          normal_JJ ._. Exclusionary_NNP laboratory_NN values_NNS included_VBD a_DT
          platelet_NN count_NN of_IN >_NN 500_CD ,_, 000_CD /_NN mm_NN 3_CD ,_, hematocrit_NN <_NN 30_CD %_NN ,_,
          and_CC a_DT white-blood-cell_JJ count_NN <_NN 3000_CD /_NN mm_NN 3_CD ._. Other_JJ
          exclusionary_JJ criteria_NNS included_VBD use_NN of_IN intravenous_JJ or_CC
          intra-articular_JJ corticosteroids_NNS within_IN four_CD weeks_NNS of_IN
          randomization_NN ,_, any_DT prior_JJ use_NN of_IN cyclosporine_NN or_CC
          cyclophosphamide_NN ,_, use_NN of_IN any_DT investigational_JJ agent_NN within_IN
          30_CD days_NNS of_IN randomization_NN ,_, severe_JJ extra-articular_JJ
          manifestations_NNS of_IN RA_NNP ,_, acute_JJ infection_NN requiring_VBG
          antibiotic_JJ therapy_NN within_IN two_CD weeks_NNS of_IN randomization_NN ,_,
          other_JJ autoimmune_JJ disease_NN (_( e_SYM ._. g_SYM ._. systemic_JJ lupus_JJ
          erythematosus_JJ )_) ,_, or_CC any_DT other_JJ condition_NN that_IN the_DT
          investigator_NN thought_VBD might_MD have_VB placed_VBN the_DT patient_NN at_IN
          undue_JJ risk_NN if_IN they_PRP had_VBD participated_VBN in_IN the_DT trial_NN ._. Men_NN and_CC
          women_NNS of_IN childbearing_VBG potential_NN were_VBD required_VBN to_TO use_NN
          approved_VBD methods_NNS of_IN birth_NN control_NN ._. Women_NNP had_VBD to_TO have_VB a_DT
          negative_JJ result_NN on_IN a_DT test_NN of_IN serum_NN beta_NN human_JJ chorionic_JJ
          gonadotropin_NN at_IN screening_NN ._.
          Medications_NNP including_VBG cyclosporine_NN ,_, cyclophosphamide_NN ,_,
          and_CC any_DT DMARD_NNP were_VBD not_RB allowed_VBN ._. The_DT use_NN of_IN intravenous_JJ or_CC
          intra-articular_JJ corticosteroids_NNS was_VBD not_RB permitted_VBN ._. The_DT
          following_VBG analgesics_NNS were_VBD permitted_VBN :_: acetaminophen_NN ,_,
          acetaminophen_NN with_IN codeine_NN ,_, acetaminophen_NN with_IN oxycodone_NN ,_,
          and_CC propoxyphene_NN ._. Patients_NNS were_VBD instructed_VBN not_RB to_TO take_VB
          analgesics_NNS within_IN 12_CD hours_NNS of_IN their_PRP$ planned_VBN study_NN
          visit_NN ._.
        
        
          Study_NN protocol_NN
          An_DT Institutional_NNP Review_NNP Board_NNP approved_VBD the_DT protocol_NN at_IN
          each_DT of_IN the_DT 12_CD participating_VBG centers_NNS ._. Patients_NNS gave_VBD prior_RB
          written_VBN ,_, informed_VBN consent_NN to_TO any_DT study-related_JJ
          procedures_NNS ._. Within_IN 14_CD days_NNS before_IN randomization_NN ,_, patients_NNS
          had_VBD a_DT complete_JJ medical_JJ history_NN taken_VBN and_CC a_DT complete_JJ
          physical_JJ examination_NN ._. A_DT standard_JJ hematology_NN profile_NN was_VBD
          prepared_VBN ,_, including_VBG white-blood-cell_JJ count_NN with_IN
          differential_NN count_NN ,_, and_CC a_DT serum-chemistry_JJ profile_NN was_VBD
          prepared_VBN ,_, consisting_VBG of_IN sodium_NN ,_, potassium_NN ,_, chloride_NN ,_,
          blood_NN urea_NN nitrogen_NN ,_, creatinine_NN ,_, glucose_NN ,_, phosphorus_JJ ,_,
          total_JJ bilirubin_NN ,_, alkaline_NN phosphatase_NN ,_, aspartate_NN
          aminotransferase_NN ,_, alanine_NN aminotransferase_NN ,_, albumin_NN ,_, uric_JJ
          acid_NN ,_, total_JJ protein_NN ,_, C-_NNP reactive_JJ protein_NN (_( CRP_NNP )_) ,_,
          fibrinogen_NN ,_, and_CC a_DT microscopic_JJ urinalysis_NNS ._. An_DT additional_JJ
          serum_NN specimen_NN was_VBD taken_VBN on_IN days_NNS 1_CD ,_, 28_CD ,_, 84_CD ,_, and_CC 112_CD to_TO
          measure_VB for_IN the_DT presence_NN of_IN IL-_NNP 6_CD ._. Screening_NNP clinical_JJ
          assessments_NNS included_VBD vital_JJ signs_NNS ,_, counts_NNS of_IN tender_NN and_CC
          swollen_JJ joints_NNS ,_, the_DT patient_NN 's_POS global_JJ assessment_NN and_CC
          assessment_NN of_IN their_PRP$ pain_NN ,_, and_CC a_DT physician_NN 's_POS global_JJ
          assessment_NN using_VBG a_DT 7_CD -_: point_NN Likert_NNP scale_NN (_( 0_CD =_SYM none_NN ,_, or_CC
          good_JJ ,_, to_TO 7_CD =_SYM severe_JJ ,_, or_CC very_RB bad_JJ )_) ._. Rheumatoid_NNP factor_NN was_VBD
          also_RB measured_VBN ._. A_DT serum_NN pregnancy_NN test_NN was_VBD done_VBN in_IN all_DT
          female_JJ patients_NNS of_IN childbearing_VBG potential_JJ ._. Disease_NN
          activity_NN and_CC clinical_JJ laboratory_NN values_NNS were_VBD assessed_VBN
          again_RB on_IN day_NN 1_CD ,_, and_CC then_RB every_DT 2_CD weeks_NNS for_IN 12_CD weeks_NNS ,_, and_CC
          at_IN 4_CD weeks_NNS post_NN dosing_VBG ._. Day-_NNP 1_CD procedures_NNS were_VBD performed_VBN
          before_IN the_DT first_JJ dose_NN of_IN study_NN drug_NN was_VBD administered_VBN ._.
          Rheumatologists_NNP or_CC trained_VBN study_NN coordinators_NNS
          performed_VBD clinical_JJ assessments_NNS ._. To_TO minimize_VB variability_NN ,_,
          the_DT same_JJ person_NN assessed_VBD disease_NN activity_NN during_IN the_DT
          trial_NN whenever_WRB possible_JJ ._.
          Patients_NNS could_MD withdraw_VB from_IN the_DT trial_NN at_IN any_DT time_NN for_IN
          any_DT of_IN the_DT following_JJ reasons_NNS :_: at_IN the_DT patient_NN 's_POS request_NN ,_,
          if_IN a_DT serious_JJ adverse_JJ event_NN occurred_VBD ,_, if_IN a_DT concomitant_NN
          medication_NN not_RB permitted_VBN by_IN the_DT protocol_NN was_VBD required_VBN ,_, or_CC
          if_IN a_DT patient_NN became_VBD pregnant_JJ ,_, did_VBD not_RB comply_VB with_IN
          study-related_JJ procedures_NNS ,_, or_CC needed_VBD surgery_NN ._.
        
        
          Treatment_NNP
          Twelve_CD centers_VBZ randomized_JJ patients_NNS ,_, using_VBG a_DT central_JJ
          randomization_NN to_TO one_CD of_IN five_CD treatment_NN groups_NNS :_: placebo_NN ,_,
          2_CD ._. 5_CD or_CC 7_CD ._. 5_CD μg_NN /_NN kg_NN of_IN rhIL-_NN 11_CD twice_RB per_IN week_NN ,_, or_CC 5_CD ._. 0_CD or_CC 15_CD
          μg_NN /_NN kg_NN of_IN rhIL-_NN 11_CD given_VBN subcutaneously_RB once_RB per_IN week_NN ._. The_DT
          maximum_NN dose_NN in_IN any_DT single_JJ injection_NN was_VBD 1000_CD μg_NN ._. The_DT
          study_NN coordinator_NN taught_VBD patients_NNS how_WRB to_TO administer_VB the_DT
          study_NN drug_NN subcutaneously_RB themselves_PRP ._. Either_CC rhIL-_NN 11_CD or_CC a_DT
          placebo_NN (_( saline_NN )_) was_VBD supplied_VBN as_IN 1_CD mg_NN lyophilized_JJ powder_NN
          in_IN a_DT phosphate_NN /_NN glycine_NN formulation_NN and_CC reconstituted_JJ with_IN
          1_CD ml_NN water_NN for_IN injection_NN ._.
        
        
          Statistical_NNP analysis_NN
          The_DT primary_JJ objective_NN of_IN this_DT trial_NN was_VBD to_TO evaluate_VB
          the_DT safety_NN and_CC tolerability_NN of_IN rhIL-_NN 11_CD given_VBN to_TO patients_NNS
          with_IN active_JJ RA_NNP ._. The_DT safety_NN endpoints_NNS were_VBD the_DT incidence_NN
          and_CC severity_NN of_IN reported_VBD adverse_JJ events_NNS and_CC abnormal_JJ
          laboratory_NN findings_NNS ._. Adverse_JJ events_NNS are_VBP reported_VBN without_IN
          regard_NN to_TO causality_NN and_CC are_VBP described_VBN for_IN the_DT study_NN as_IN a_DT
          whole_JJ and_CC by_IN treatment_NN group_NN ._. Descriptive_NNP statistics_NNS
          summarizing_VBG the_DT incidence_NN and_CC severity_NN of_IN adverse_JJ events_NNS
          are_VBP presented_VBN ._.
          The_DT secondary_JJ objective_NN of_IN this_DT trial_NN was_VBD to_TO evaluate_VB
          and_CC characterize_VB the_DT clinical_JJ activity_NN of_IN rhIL-_NN 11_CD ._. The_DT
          endpoint_NN used_VBN to_TO characterize_VB clinical_JJ activity_NN was_VBD the_DT
          proportion_NN of_IN patients_NNS whose_WP$ disease_NN improved_VBD according_VBG
          to_TO the_DT 20_CD %_NN ACR_NNP criteria_NNS [_NN 16_CD ]_NN ._. The_DT overall_JJ proportion_NN of_IN
          patients_NNS whose_WP$ disease_NN improved_VBN within_IN each_DT individual_JJ
          category_NN of_IN the_DT ACR_NNP criteria_NNS is_VBZ also_RB presented_VBN ._.
          Exploratory_NNP comparative_JJ tests_NNS on_IN differences_NNS in_IN the_DT
          proportions_NNS of_IN improvement_NN between_IN the_DT rhIL-_NN 11_CD -_: treated_VBN
          groups_NNS and_CC the_DT placebo_NN group_NN were_VBD done_VBN ,_, using_VBG a_DT two-sided_JJ
          Fisher_NNP 's_POS exact_JJ test_NN ._. Logistic_NNP regression_NN was_VBD used_VBN to_TO
          explore_VB the_DT effect_NN of_IN total_JJ weekly_JJ dose_NN ,_, dosing_VBG schedule_NN ,_,
          treatment_NN duration_NN ,_, and_CC outcome_NN on_IN clinical_JJ activity_NN ._.
          Missing_NNP data_NNS were_VBD handled_VBN by_IN both_DT the_DT ad_NN hoc_FW
          last-observation-carried-forward_JJ method_NN and_CC the_DT
          worst-case-scenario_JJ method_NN ._. In_IN the_DT
          last-observation-carried-forward_JJ approach_NN ,_, when_WRB an_DT
          observation_NN for_IN a_DT 12_CD -_: week_NN time_NN point_NN was_VBD lacking_VBG for_IN a_DT
          patient_NN ,_, the_DT last_JJ available_JJ observed_JJ value_NN was_VBD carried_VBN
          forward_RB ._. In_IN the_DT worst-case-scenario_JJ approach_NN ,_, dropouts_NNS
          were_VBD treated_VBN as_IN failures_NNS ._. The_DT sample_NN size_NN was_VBD based_VBN on_IN an_DT
          assumed_VBN 10_CD %_NN placebo_NN success_NN rate_NN ._. The_DT sample_NN size_NN had_VBD a_DT
          >_NN 80_CD %_NN power_NN to_TO detect_VB a_DT 0_CD ._. 51_CD difference_NN from_IN the_DT
          placebo_NN success_NN rate_NN in_IN at_IN least_JJS one_CD of_IN the_DT rhIL-_NN 11_CD
          treatment_NN groups_NNS at_IN the_DT α_NN =_SYM 0_CD ._. 05_CD level_NN of_IN
          significance_NN ._.
        
      
      
        Results_NNS
        
          Characteristics_NNP of_IN patients_NNS
          The_DT pretherapy_NN characteristics_NNS of_IN the_DT patients_NNS are_VBP
          summarized_VBD in_IN Table_NNP 1_CD ._. Sixty-seven_NNP women_NNS and_CC 24_CD men_NNS were_VBD
          randomized_JJ to_TO the_DT study_NN and_CC 90_CD patients_NNS received_VBD at_IN least_JJS
          one_CD dose_NN of_IN study_NN drug_NN ._. One_CD patient_NN was_VBD randomized_JJ but_CC
          never_RB received_VBD the_DT study_NN drug_NN as_IN they_PRP withdrew_VBD consent_NN
          prior_RB to_TO treatment_NN ._. The_DT mean_JJ age_NN of_IN all_DT patients_NNS was_VBD 51_CD
          years_NNS (_( range_NN 21_CD -_: 83_CD )_) and_CC the_DT mean_JJ time_NN since_IN diagnosis_NN was_VBD
          12_CD ._. 6_CD years_NNS (_( range_NN 1_CD ._. 2_CD -_: 40_CD ._. 3_LS )_) ._. No_DT significant_JJ differences_NNS
          between_IN the_DT pretherapy_NN characteristics_NNS of_IN men_NNS and_CC women_NNS
          were_VBD noted_VBN ._. The_DT mean_NN numbers_NNS of_IN tender_NN and_CC swollen_JJ joints_NNS
          in_IN all_DT patients_NNS at_IN screening_NN were_VBD 27_CD and_CC 20_CD ,_,
          respectively_RB ._. Forty-nine_NNP of_IN the_DT 90_CD patients_NNS (_( 54_CD ._. 4_LS %_NN )_) who_WP
          were_VBD dosed_JJ completed_VBN 12_CD weeks_NNS of_IN dosing_VBG ._. The_DT majority_NN of_IN
          patients_NNS (_( 24_CD of_IN 41_CD or_CC 58_CD ._. 5_LS %_NN )_) who_WP discontinued_VBN early_RB
          withdrew_VBD due_JJ to_TO lack_NN of_IN clinical_JJ effect_NN ._. Eleven_CD patients_NNS
          (_( 12_CD ._. 2_LS %_NN )_) withdrew_VBD because_IN of_IN adverse_JJ events_NNS ._. Of_IN the_DT
          remaining_VBG six_CD patients_NNS ,_, four_CD withdrew_VBD their_PRP$ consent_NN ,_, one_CD
          was_VBD lost_VBN to_TO follow-up_JJ ,_, and_CC one_CD received_VBD a_DT prohibited_VBN
          medication_NN ._. Patients_NNS who_WP discontinued_VBN from_IN the_DT trial_NN were_VBD
          evenly_RB distributed_VBN among_IN all_PDT the_DT treatment_NN groups_NNS ._.
        
        
          Safety_NNP
          rhIL-_NN 11_CD was_VBD well_RB tolerated_JJ ._. No_DT dose-limiting_JJ
          toxicities_NNS were_VBD observed_VBN ._. In_IN the_DT 11_CD patients_NNS who_WP withdrew_VBD
          because_IN of_IN an_DT adverse_JJ event_NN ,_, none_NN of_IN these_DT events_NNS were_VBD
          considered_VBN to_TO be_VB drug_NN related_VBN ._. One_CD patient_NN died_VBD during_IN
          the_DT study_NN ,_, from_IN complications_NNS associated_VBN with_IN a_DT
          spontaneous_JJ pneumothorax_NN ;_: this_DT patient_NN was_VBD in_IN the_DT placebo_NN
          group_NN ._. The_DT only_RB adverse_JJ events_NNS clearly_RB related_VBN to_TO rhIL-_NN 11_CD
          were_VBD reactions_NNS at_IN the_DT injection_NN site_NN ,_, which_WDT were_VBD seen_VBN in_IN
          60_CD ._. 6_CD %_NN (_( 43_CD of_IN 71_CD )_) of_IN patients_NNS who_WP received_VBD rhIL-_NN 11_CD and_CC
          none_NN of_IN the_DT 19_CD placebo_NN recipients_NNS ._. The_DT incidence_NN of_IN
          injection-site_JJ reactions_NNS was_VBD not_RB related_VBN to_TO any_DT dose_NN or_CC
          schedule_NN ._. These_DT reactions_NNS (_( erythema_NN or_CC erythema_NN with_IN
          induration_NN )_) were_VBD mild_JJ and_CC resolved_VBN within_IN days_NNS after_IN the_DT
          study_NN drug_NN was_VBD discontinued_VBN ._. There_EX were_VBD no_DT statistically_RB
          significant_JJ differences_NNS in_IN the_DT incidences_NNS of_IN respiratory_JJ
          infections_NNS ,_, non-respiratory_JJ infections_NNS ,_, or_CC edema_NN ._. A_DT
          higher_JJR incidence_NN of_IN infection_NN in_IN the_DT rhIL-_NN 11_CD treated_VBN
          group_NN (_( 7_CD ._. 8_CD %_NN )_) than_IN in_IN the_DT placebo_NN group_NN (_( 0_CD %_NN )_) was_VBD not_RB
          statistically_RB significant_JJ (_( 
          P_NN =_SYM 0_CD ._. 34_CD )_) ._. Clinical_NNP trials_NNS with_IN
          other_JJ agents_NNS that_WDT affect_VBP levels_NNS of_IN circulating_VBG TNF-α_NNP have_VBP
          also_RB found_VBN more_RBR frequent_JJ ,_, nonstatistical_JJ differences_NNS in_IN
          the_DT incidence_NN of_IN upper-respiratory_JJ infections_NNS [_NN 11_CD ]_NN ._.
          Adverse_JJ events_NNS occurring_VBG in_IN more_JJR than_IN 5_CD %_NN of_IN patients_NNS are_VBP
          summarized_VBD in_IN Table_NNP 2_CD ._.
          No_DT significant_JJ changes_NNS in_IN hematology_NN or_CC chemistry_NN
          parameters_NNS were_VBD noted_VBN during_IN the_DT study_NN ._. There_EX were_VBD no_DT
          statistically_RB significant_JJ changes_NNS in_IN fibrinogen_NN levels_NNS or_CC
          platelet_NN counts_VBZ in_IN rhIL-_NN 11_CD treated_VBN patients_NNS compared_VBN with_IN
          placebo_NN during_IN the_DT study_NN at_IN all_DT doses_NNS and_CC schedules_NNS ._.
        
        
          Disease_NN activity_NN
          No_DT clear_JJ therapeutic_JJ effect_NN associated_VBN with_IN the_DT
          administration_NN of_IN rhIL-_NN 11_CD was_VBD observed_VBN ._. Figure_NN 1_CD describes_VBZ
          the_DT data_NNS using_VBG the_DT 20_CD %_NN ACR_NNP criteria_NNS for_IN response_NN at_IN the_DT
          various_JJ doses_NNS or_CC schedules_NNS tested_VBN ._. The_DT placebo_NN response_NN
          rate_NN at_IN the_DT 20_CD %_NN improvement_NN criteria_NNS was_VBD unusually_RB high_JJ
          (_( 32_CD %_NN )_) for_IN a_DT placebo-controlled_JJ trial_NN ._. Several_JJ (_( 6_CD /_NN 19_CD )_)
          patients_NNS in_IN the_DT placebo_NN group_NN experienced_VBD a_DT significant_JJ
          (_( >_NN 50_CD %_NN )_) improvement_NN in_IN their_PRP$ tender-_NN and_CC swollen-joint_JJ
          counts_NNS during_IN the_DT study_NN ._. These_DT findings_NNS in_IN the_DT placebo_NN
          group_NN obscure_VB any_DT comparative_JJ rhIL-_NN 11_CD benefit_NN ._. Values_NNP for_IN
          placebo-treated_JJ patients_NNS regressed_JJ towards_IN baseline_NN
          during_IN the_DT follow-up_JJ period_NN in_IN all_DT analyses_NNS
          performed_VBN ._.
          The_DT group_NN treated_VBN with_IN rhIL-_NN 11_CD at_IN 15_CD μg_NN /_NN kg_NN once_RB per_IN
          week_NN produced_VBD a_DT statistically_RB significant_JJ improvement_NN in_IN
          tender-joint_JJ counts_VBZ (_( 
          P_NN =_SYM 0_CD ._. 007_CD )_) at_IN 12_CD weeks_NNS (_( Figure_NN 1_LS )_) ._.
          The_DT mean_JJ percentage_NN of_IN improvement_NN in_IN the_DT tender-joint_JJ
          count_NN at_IN this_DT dose_NN and_CC schedule_NN was_VBD 31_CD ._. 8_CD (_( Figure_NN 2_LS )_) ._. This_DT
          trend_NN was_VBD consistent_JJ when_WRB an_DT intent-to-treat_JJ (_( ITT_NNP )_)
          analysis_NN was_VBD used_VBN to_TO evaluate_VB changes_NNS from_IN baseline_NN in_IN
          tender-joint_JJ count_NN in_IN all_DT rhIL-_NN 11_CD treated_VBN cohorts_NNS (_( 
          P_NN <_NN 0_CD ._. 015_CD )_) ._. There_EX is_VBZ no_DT obvious_JJ
          reason_NN why_WRB an_DT improvement_NN in_IN tender-joint_JJ count_NN were_VBD not_RB
          mirrored_VBD by_IN changes_NNS in_IN other_JJ clinical_JJ measurements_NNS ._.
          Comparative_NNP assessment_NN (_( unadjusted_JJ for_IN multiple_JJ
          comparisons_NNS )_) at_IN the_DT end-of-treatment_JJ time_NN point_NN revealed_VBD
          statistically_RB significant_JJ correlations_NNS between_IN serum_NN
          levels_NNS of_IN IL-_NNP 6_CD and_CC CRP_NNP to_TO each_DT of_IN the_DT six_CD clinical_JJ
          outcomes_NNS (_( tender-joint_JJ count_NN ,_, swollen-joint_JJ count_NN ,_,
          patient_NN 's_POS global_JJ assessment_NN ,_, patient_NN 's_POS assessment_NN of_IN
          pain_NN ,_, physician_NN 's_POS global_JJ assessment_NN ,_, score_NN on_IN
          health-assessment_JJ questionnaire_NN )_) ._. Correlation_NNP
          coefficients_NNS were_VBD moderate_JJ (_( 
          r_LS =_SYM 0_CD ._. 24_CD -_: 0_CD ._. 42_CD )_) and_CC all_DT
          corresponding_JJ ,_, unadjusted_JJ ,_, 
          P_NN -_: values_NNS were_VBD less_JJR than_IN 0_CD ._. 03_CD ._.
          These_DT were_VBD :_: tender-joint_JJ count_NN versus_CC IL-_NNP 6_CD (_( 
          P_NN =_SYM 0_CD ._. 003_CD )_) ;_: swollen-joint_JJ count_NN
          versus_CC IL-_NNP 6_CD (_( 
          P_NN =_SYM 0_CD ._. 026_CD )_) ;_: tender-joint_JJ count_NN
          versus_CC CRP_NNP (_( 
          P_NN =_SYM 0_CD ._. 001_CD )_) ;_: swollen-joint_JJ count_NN
          versus_CC CRP_NNP (_( 
          P_NN =_SYM 0_CD ._. 002_CD )_) ._. 
          P_NN -_: values_NNS of_IN comparisons_NNS between_IN
          the_DT other_JJ four_CD clinical_JJ assessments_NNS and_CC IL-_NNP 6_CD /_NN CRP_NNP were_VBD
          stronger_JJR ,_, with_IN all_DT =_SYM 0_CD ._. 001_CD ._.
        
        
          Discussion_NNP
          In_IN this_DT study_NN ,_, no_DT therapeutic_JJ benefit_NN of_IN rhIL-_NN 11_CD (_( at_IN
          the_DT doses_NNS and_CC frequencies_NNS of_IN administration_NN studied_VBN )_) was_VBD
          found_VBN ._. Some_DT individual_JJ measurements_NNS of_IN therapeutic_JJ effect_NN
          (_( tender-joint_JJ counts_VBZ )_) and_CC biologic_JJ activity_NN (_( IL-_NNP 6_CD levels_NNS )_)
          were_VBD observed_VBN ._. rhIL-_NN 11_CD was_VBD well_RB tolerated_JJ at_IN all_DT
          doses_NNS ._.
          Except_IN for_IN the_DT tender-joint_JJ count_NN ,_, none_NN of_IN the_DT
          observed_VBN disease_NN activities_NNS was_VBD statistically_RB different_JJ
          from_IN placebo_NN according_VBG to_TO the_DT ACR_NNP criteria_NNS at_IN the_DT 20_CD %_NN
          improvement_NN level_NN ._. The_DT inability_NN of_IN rhIL-_NN 11_CD to_TO bring_VB
          about_IN a_DT statistically_RB significant_JJ improvement_NN in_IN the_DT ACR_NNP
          20_CD %_NN criteria_NNS may_MD also_RB be_VB the_DT result_NN of_IN an_DT inability_NN of_IN
          rhIL-_NN 11_CD to_TO stimulate_VB the_DT synthesis_NN of_IN acute-phase_JJ
          proteins_NNS ,_, of_IN the_DT significant_JJ clinical_JJ response_NN of_IN several_JJ
          placebo-treated_JJ patients_NNS ,_, or_CC of_IN a_DT lack_NN of_IN adequate_JJ power_NN
          of_IN the_DT study_NN to_TO show_VB efficacy_NN ._. Larger_NNP clinical_JJ trails_NNS of_IN
          rhIL-_NN 11_CD at_IN higher_JJR or_CC more_RBR frequent_JJ dosing_VBG intervals_NNS and_CC
          for_IN a_DT longer_RBR dosing_VBG period_NN may_MD provide_VB more_RBR definitive_JJ
          data_NNS on_IN the_DT safety_NN and_CC efficacy_NN of_IN rhIL-_NN 11_CD in_IN the_DT
          treatment_NN of_IN patients_NNS with_IN RA_NNP ._.
          The_DT mechanism_NN of_IN action_NN of_IN rhIL-_NN 11_CD in_IN the_DT treatment_NN of_IN
          active_JJ RA_NNP most_RBS likely_JJ results_NNS from_IN the_DT ability_NN of_IN rhIL-_NN 11_CD
          to_TO reduce_VB levels_NNS of_IN TNF-α_NNP ,_, IL-_NNP 1_CD β_NN ,_, and_CC IL-_NNP 12_CD p_NN 40_CD ._. The_DT
          anti-inflammatory_JJ activity_NN of_IN rhIL-_NN 11_CD is_VBZ mediated_JJ in_IN part_NN
          by_IN inhibition_NN of_IN NF-κB-dependent_NNP transcriptional_NN
          activation_NN of_IN proinflammatory_NN cytokine_NN genes_NNS ._. The_DT ability_NN
          of_IN rhIL-_NN 11_CD to_TO affect_VB levels_NNS of_IN IL-_NNP 6_CD is_VBZ also_RB probably_RB
          mediated_JJ through_IN this_DT mechanism_NN ._. An_DT analysis_NN of_IN
          pharmacodynamic_JJ markers_NNS in_IN skin_NN biopsies_NNS obtained_VBN from_IN
          patients_NNS with_IN moderate_JJ psoriasis_NNS treated_VBN with_IN rhIL-_NN 11_CD
          revealed_VBD lower_JJR levels_NNS of_IN INF-γ_NNP ,_, TNF-α_NNP ,_, and_CC inducible_JJ
          nitric_JJ oxide_NN than_IN before_IN treatment_NN ._.
        
      
      
        Conclusion_NNP
        These_DT preliminary_JJ data_NN suggest_VBP that_DT rhIL-_NN 11_CD may_MD be_VB
        safely_RB administered_VBN to_TO patients_NNS with_IN active_JJ RA_NNP at_IN a_DT variety_NN
        of_IN doses_NNS and_CC schedules_NNS ._. No_DT dose-limiting_JJ adverse_JJ event_NN was_VBD
        observed_VBN ._. The_DT dose_NN of_IN 15_CD μg_NN /_NN kg_NN of_IN rhIL-_NN 11_CD once_RB per_IN week_NN
        suggested_VBD a_DT minimal_JJ therapeutic_JJ effect_NN ,_, an_DT improvement_NN in_IN
        tender-joint_JJ counts_NNS ._. Further_RB studies_VBZ are_VBP warranted_VBN to_TO find_VB
        out_IN if_IN higher_JJR or_CC more_RBR frequent_JJ doses_NNS of_IN rhIL-_NN 11_CD may_MD be_VB safe_JJ
        and_CC efficacious_JJ in_IN treating_VBG RA_NNP ._.
      
      
        Abbreviations_NNP
        ACR_NNP =_SYM American_NNP College_NNP of_IN Rheumatology_NNP ;_: CRP_NNP =_SYM C-_NNP reactive_JJ
        protein_NN ;_: DMARD_NNP =_SYM disease-modifying_JJ antirheumatic_JJ drug_NN ;_: IL_NNP =_SYM
        interleukin_NN ;_: NF_NNP =_SYM nuclear_JJ factor_NN ;_: RA_NNP =_SYM rheumatoid_NN
        arthritis_NN ;_: rhIL-_NN 11_CD =_SYM recombinant_JJ human_JJ IL-_NNP 11_CD ;_: TNF_NNP =_SYM tumor_NN
        necrosis_NNS factor_NN ._.
      
    
  
